|
Market Cap (3-Jul) $8,006,598,144 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (19-Jun) 16,724,445 (4.94%) (48th) |
|
52w High $31.97 |
52w Low $17.03 |
P/E 56.82 |
EPS 0.14 |
TLX released this announcement to the ASX on 15 September 2021, 8:23. The announcement is not marked as price sensitive, and is 2 page(s) in length and 200.41kb in size.
You can view all announcements from TLX and see how they appear on a price chart on the announcements page.
At the date of this announcement, TLX was 0.260% short sold according to ASIC data. It was ranked the 340th most shorted stock on the ASX. It is now ranked as the 48th most shorted stock on the ASX with 4.944% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from TLX | |
|---|---|
| Cleansing Notice | 28 June 2023, 8:23 |
| Application for quotation of securities - TLX | 28 June 2023, 8:23 |
| Proposed issue of securities - TLX | 21 June 2023, 18:12 |
| Telix Supporting Amgen PSMA-Targeting Therapy Trial | 15 September 2021, 8:23 |
| NCCN Guidelines updated to include PSMA-PET Imaging | 14 September 2021, 10:00 |
| FDA Approves Phase II Kidney Cancer Therapy Study | 14 September 2021, 8:22 |
| Telix and Radius sign Distribution Agreement for Italy | 13 September 2021, 8:21 |
You must be logged in to post a reply.
Telix Pharmaceuticals 